Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)

Christina Messiou, MD • Jens Hillengass, MD • Stefan Delorme, MD • Frédéric E. Lecouvel, MD • Lia A. Moulopoulos, MD • David J. Collins, BA • Matthew D. Blackledge, PhD • Niels Abildgaard, MD • Brian Østergaard, MD • Heinz-Peter Schlemmer, MD • Ola Landgren, MD • Jon Thor Asmussen, MD • Martin F. Kaiser, MD • Anwar Padhani, MD

From the Department of Radiology, Royal Marsden Hospital and Institute of Cancer Research, Downs Rd, Sutton SM2 5PT, England (C.M., M.D.B., M.F.K.); Roswell Park Comprehensive Cancer Center, Buffalo, NY (J.H.); Department of Radiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany (S.D., H.P.S.); Department of Radiology, Cancer Center and Institute of Experimental and Clinical Research, Brussels, Belgium (F.E.L.); Department of Radiology, National and Kapodistrian University of Athens, Athens, Greece (L.I.A.); Royal Marsden Hospital, London, England (D.J.C.); Odense University Hospital, Odense, Denmark (N.A., J.T.A.); Vejle Hospital, Vejle, Denmark (B.O.); Memorial Sloan-Kettering Cancer Center, New York, NY (O.L.); and Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, England (A.E.). Received August 30, 2018; revision requested October 10; final revision received October 26; accepted October 30. Address correspondence to C.M. (e-mail: Christina.Messiou@rmh.nhs.uk).

Study supported by National Health Service funding to the National Institute for Health Research Biomedical Research Centre, Clinical Research Facility in Imaging at The Royal Marsden Hospital, and the Cancer Research Network. This report is independent research funded by the National Institute for Health Research. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.

Conflicts of interest are listed at the end of this article.

Radiology 2019; 291:5–13 • https://doi.org/10.1148/radiol.2019181949 • Content code: MR

Acknowledging the increasingly important role of whole-body MRI for directing patient care in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical physicists, and hematologists with specific expertise in whole-body MRI in myeloma convened to discuss the technical performance standards, merits, and limitations of currently available imaging methods. Following guidance from the International Myeloma Working Group and the National Institute for Clinical Excellence in the United Kingdom, the Myeloma Response Assessment and Diagnosis System (or MY-RADS) imaging recommendations are designed to promote standardization and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI in myeloma and allow response assessment. This consensus proposes a core clinical protocol for whole-body MRI and an extended protocol for advanced assessments.

Published under a CC BY 4.0 license.

Online supplemental material is available for this article.

Online SA-CME • See www.rsna.org/learning-center-ry

Learning Objectives:
After reading the article and taking the test, the reader will be able to:
- Describe different patterns of myeloma infiltration on whole-body MR images
- List the components of the whole-body MRI protocol
- Describe how whole-body MRI should be used to assess response to treatment

Accreditation and Designation Statement
The RSNA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The RSNA designates this journal-based SA-CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement
The ACCME requires that the RSNA, as an accredited provider of CME, obtain signed disclosure statements from the authors, editors, and reviewers for this activity. For this journal-based CME activity, author disclosures are listed at the end of this article.

Laboratory assessments of myeloma disease activity directly impact treatment decisions in multiple myeloma (1) and contribute to clinical risk stratification systems such as the Revised International Staging System for Multiple Myeloma and gene expression profiling classifiers (2,3). Conversely, skeletal survey, which has been in widespread use for decades, only offers a crude assessment of bone involvement as a myeloma-defining event. More recently, some centers have escalated imaging by replacing skeletal survey with low-dose whole-body CT, which has greater sensitivity (4). However, because skeletal survey and CT predominantly help to detect the destructive effects of myeloma disease on trabecular and cortical bone rather than disease within the bone marrow space, sensitivity and capability as a restaging tool are inherently limited (5,6) (although imaging of bone destruction may be helpful for surgical planning). Myeloma infiltrates within bone marrow can be depicted with CT if they lie within the marrow spaces of long bones where they stand out against fatty bone marrow (7). However, in trabecular bone such as in the vertebral bodies, myeloma infiltrates are difficult to assess due to the trabeculae themselves and

This copy is for personal use only. To order printed copies, contact reprints@rsna.org
Whole-body MRI as currently used includes DW MRI sequences that are sensitive to cellular density and viability and are important for disease detection, monitoring, and therapy response assessments. Inclusion of DW MRI allows highly sensitive and quantitative evaluation of soft tissue and bone marrow, which is widely available and quick to perform and interpret. The relationship of apparent diffusion coefficient (ADC) (in square micrometers per second) values with cell density permits response assessments ahead of changes in lesion size, in addition to assessments of response heterogeneity (8,30–32).

Whole-body MRI including DW MRI has become established as the most sensitive technique for bone marrow imaging (23–25) with additional benefits of speed, coverage, and quantification in comparison with traditional MRI, obviating intravenous injections and radiation exposure. Wide anatomic coverage is essential because 50% of lesions would be missed by imaging the spine alone (33). Avoidance of ionizing radiation is likely to become increasingly relevant as surveillance imaging of high-risk patients with monoclonal gammopathy of undetermined significance and of those with smoldering disease gains momentum.

Whole-body MRI is a generally well-tolerated technique (24) that offers the additional benefits of assessing skeletal complications, such as spinal canal and/or nerve root compression, and is the most accurate method for differentiating benign from malignant vertebral compression fractures (34).

Although the International Myeloma Working Group has taken a pragmatic approach in recommending a range of possible imaging investigations (including low-dose CT, FDG PET/CT, and MRI) for patients with a new potential diagnosis of myeloma, the high sensitivity of whole-body MRI is explicitly acknowledged (6,35) and it is now recommended as first-line imaging for all patients with a suspected diagnosis of asymptomatic myeloma or solitary bone plasmacytoma. In the United Kingdom, whole-body MRI is recommended as first-line imaging for all patients with a suspected new diagnosis of myeloma (26). Recently, the British Society for Haematology additionally recommended the use of whole-body MRI for monitoring response of nonsecretory myeloma, oligosecretory myeloma (which can occur at relapse in patients with previous secretory disease), and for those patients with extramedullary disease (36). The uses of whole-body MRI in myeloma are summarized in Figure 1.

Acknowledging the increasingly important role of whole-body MRI for directing patient care in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical physicists, and hematologists with experience in whole-body MRI in myeloma convened to discuss the performance standards, merits, and limitations of currently available imaging methods. The recently published Metastasis Reporting and Data System for Prostate Cancer, or MET-RADS, guidelines on the use of whole-body MRI for metastasis evaluations (37) were used as a model to formulate the performance standards for whole-body MRI use in the assessment of involvement by myeloma. The Myeloma Response Assessment and Diagnosis System (MY-RADS) imaging recommendations are designed to promote standardization and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI in myeloma. The system also provides a means for accurate and reproducible reporting of whole-body MRI in myeloma.
Whole-Body MRI Data Acquisition and Analysis

The core clinical protocol for whole-body MRI when used alone is designed for myeloma detection in bone marrow but can also image extramedullary disease and should be completed within 30 minutes of imaging time (Table 1). More comprehensive assessments can be performed within 45–50 minutes of imaging time (Table 1). Details of machine setup, sequence specification, quality assurance procedures, and quality control and radiographic aspects can be found in Table E3 (Appendix E1 [online]).

The core protocol for whole-body MRI is adequate for the detection of disease at diagnosis. Comprehensive assessments are recommended for assessment of soft tissue, extramedullary disease, or for those patients in whom serial tumor response assessments (including clinical trials) are planned.

Clinical Information

The following information should ideally be available to radiologists at the time of reporting (and increasing use of electronic patient records increases the feasibility of this): time of initial diagnosis or suspected diagnosis, serum paraprotein levels and light chain levels and trephine status (if performed, including site), symptomatic sites including any clinical indication of cord or nerve root compression, first line or relapse state, current treatment, history of autograft or allograft transplant, details of previous radiation therapy or surgical interventions including vertebroplasty, granulocyte colony–stimulating factor or steroid administration, and minimal residual disease status (if performed).

Assessing Images from Whole-Body MRI

Multisequence evaluations should be performed by using all images from DW MRI (low, intermediate [if obtained], and high b-values and ADC maps) in conjunction with the anatomic and fat fraction images by using image linking and scrolling workstation facilities and coregistration tools as diagnostic aids.

Maximum intensity projections of high b-value images displayed by using the inverted gray scale are useful for global tumor volume assessments and for localizing regional tumor distribution. These images are able to display disease (eg, for referring clinicians in multidisciplinary meetings or in discussion with patients), but maximum intensity projection images should not be used alone for reading because apparent false-positive and false-negative disease assessments can occur (eg, due to T2 shine-through, respiratory motion signal dephasing, sparse disease pattern) (37,38). Serial volume maximum intensity projection image comparisons can be facilitated by using windowing techniques; for example, by maintaining window width between studies but adjusting the window level to a normal tissue such as muscle or subcutaneous fat for each time point.

The evaluation of source images obtained with DW MRI sequences at b-values of 800–900 sec/mm² is based on comparing high b-value image intensity to adjacent muscle signal intensity, but assessments of ADC maps are numeric (unit, ×10⁻³ mm²/sec or ×10⁻⁵ mm²/sec [µm²/sec]).

The definitions for hypointense and hyperintense signal on images at b values of 800–900 sec/mm² remain subjective but can be gauged by using adjacent muscle as the reference background tissue (39–41).

Not all hyperintense bone lesions on high b-value images are malignant in nature. Causes for apparent high b-value focal bone lesions that are false-positive for cancer include bone marrow edema caused by fractures, osteoarthritis, infection, bone infarcts, vertebral hemangiomas, chondromas, cysts, focal fat-poor bone marrow, and artifacts around metal implants (42,43). Furthermore, successfully treated focal lesions may undergo liquid transformation and can stand out on DW images due to the T2 shine-through phenomenon.

The presence of focal bone lesions can also be obscured when background bone marrow hyperplasia occurs as the result of anemia, as a rebound after high-dose therapy, or due to use of bone marrow growth factors. This is commonly encountered after allogenic stem cell transplantation. The detection of skeletal...
Figure 2: MR images show patterns of myeloma disease. A, C, E, G, I, Axial diffusion-weighted MR images (b value of 900 sec/mm²). B, D, F, H, J, Corresponding apparent diffusion coefficient (ADC) maps. A, B, Images show appearances of normal adult bone marrow. C, D, Images demonstrate focal lesion (white arrows) greater than 5 mm, which returns higher signal intensity at b value of 900 sec/mm² than does muscle and background marrow, and which has ADC resembling soft tissue that is higher than background marrow but lower than fluid, as seen in bowel anteriorly (black arrow). E, F, Images show marrow that has diffusely higher signal intensity than does muscle and returns ADC that is similar to soft tissues. G, H, Images demonstrate focal lesion (arrows) that returns higher signal intensity than does muscle and background marrow at b value of 900 sec/mm². However, background marrow is also higher signal intensity than muscle, suggesting background diffuse marrow hypercellularity that is confirmed on ADC map. I, J, Images show widespread heterogeneity with tiny nodular areas of altered diffusion signal (≤5 mm) with preserved normal marrow between them. This variegated or micronodular pattern is confirmed on, K, water-only Dixon and, L, sagittal T1 images. M, Image shows paramedullary soft-tissue disease that is in direct continuity with marrow disease, as demonstrated around left femur in M (black arrow). In contrast, N, extramedullary disease is soft-tissue disease that is not in continuity with marrow disease, as demonstrated in M and N (white arrows), which show ischiorectal fossa and pancreatic disease, respectively.

lesions at whole-body DW imaging may also be impaired in areas of body movement such as the ribs and occasionally in the sternum, but review of the maximum intensity projections of high b-value images can be helpful. Evaluation of skull vault lesions is best performed by evaluating the axial source high b-value images and corresponding Dixon fat fraction images. The visibility of skull base disease is generally impaired because of susceptibility effects and because of the adjacent high signal intensity of the brain on high b-value images.

Strategies for mitigating false-positive results due to DW imaging hyperintensities include direct correlations with morphologic appearances, including T1-weighted spin-echo and Dixon images (44,45) and ADC values (ADC values of normal bone marrow are generally below 600–700 µm²/sec and viable tumor lies between 700–1400 µm²/sec (46,47,48). Tumor ADC values greater than or equal to 1400 µm²/sec are usually observed in treated or necrotic disease. However, myeloma is a disease where there is intermixing of myeloma cells, fat, and myeloid cells within the marrow space, the relative proportions of which can alter ADC values, which must also be considered (30,49). Every suspicious lesion on high b-value images should be evaluated with other sequences, particularly Dixon fat fraction images by using coregistration tools.

The authors also recognize there are limitations of the ADC cutoff values referred to previously, which are partly related to the fact that ADC values depend on the choice of b values of DW images used for calculations (hence, the constraints on the recommended choices of b values). The ADC values may also depend on the diffusion time achievable with diffusion sequences (which is dependent on sequence waveforms and imager specifications). Aside from imaging parameters, ADC quantification is influenced by additional factors, which are patient related caused by susceptibility effects (eg, implants, air-tissue interfaces) or motion and technique related caused by the specifications of
the MRI unit, including magnetic field strength, gradients, and coils (39). Where there are deviations from the recommended \( b \) values due to machine, software, or technical factors, then institutions can determine their own muscle-normalized high \( b \)-value signal intensity and ADC cutoff values for normal marrow and for untreated bone marrow lesions as described by Padhani et al (41).

**Size measurements.**—The International Myeloma Working Group stipulates 5 mm as the threshold for defining an unequivocal focal active lesion (Fig 2). Therefore, lesions less than or equal to 5 mm should be documented for surveillance but precise measurements not given due to limitations on image resolution. Lesions greater than 5 mm but less than 1.0 cm with appropriate signal characteristics should be documented as focal active disease, but once again, precise measurements not given.

In rare instances when there are unequivocal malignant lesions less than 1.0 cm and entry to clinical trials mandates the presence of measurable disease, a relaxation of the threshold of greater than or equal to 1.0 cm may be applied in the knowledge of the caveats on image resolution.

**Obtaining ADC values.**—ADC measurements should only be obtained from lesions or areas when water is detectable at DW imaging. Otherwise, the ADC values can be erroneous, reflecting the distribution of noise on the images.

Preferably, water signal should be detectable for the assessed region on all \( b \)-value images. However, the absence of tissue signal intensity on very high (\( b \) value of 800–900 sec/mm\(^2\)) \( b \)-value images does not in and of itself invalidate a tissue from ADC measurements. Where applicable, if signal intensity is detectable on low and intermediate \( b \)-value images, then ADC measurements should be performed. ADC is generally considered to be a parameter with good reproducibility, and the coefficient of variation in myeloma-involved bone marrow has been reported as low as 2.8% (31).

**Diffuse disease.**—For patients with a suspected new diagnosis of myeloma, diffuse disease can be suspected from diffuse decreased signal on T1 fast spin-echo or Dixon in-phase and fat-only images, and diffuse increased signal throughout the marrow relative to normal muscle on high \( b \)-value images (Fig 2) (48). Suspicion for diffuse infiltration can be documented but must be confirmed with trephine biopsy, and imaging must be performed to state whether posterior iliac crest sampling is likely to be representative. An ADC measurement using a region of interest greater than 1 cm\(^2\) of representative involved bone marrow can be measured particularly where diffuse infiltration is suspected (50).

### Table 1: Sequence Components for Whole-Body MRI Examinations

<table>
<thead>
<tr>
<th>No.</th>
<th>Sequence Description</th>
<th>Core Clinical Protocol</th>
<th>Comprehensive Assessments for Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Whole spine: sagittal, T1-weighted, fast spin-echo, section thickness of 4–5 mm</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>Whole spine: sagittal, T2, STIR or fat-suppressed T2-weighted, section thickness of 4–5 mm</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>Whole body (vertex to knees): T1-weighted, gradient-echo Dixon technique. Fat and water image reconstructions are mandatory and should be used to generate fat fraction maps (FF = ( F/(F+W) \times 100% )). (A 3D fast spin-echo T1-weighted sequence offering multiplanar capability may be performed as an alternative to replace sequences 1 and 3.)</td>
<td>Axial or coronal (5 mm)†</td>
<td>Axial and coronal</td>
</tr>
<tr>
<td>4</td>
<td>Whole body (vertex to knees): axial, diffusion-weighted, STIR fat suppression, 5 mm contiguous sectioning, multiple stations.</td>
<td>2 ( b ) values (50–100 sec/mm(^2) and 800–900 sec/mm(^2))</td>
<td>3 ( b ) values (additional 500–600 sec/mm(^2))</td>
</tr>
<tr>
<td></td>
<td>ADC calculations with monoexponential data fitting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3D MIP reconstructions of highest ( b )-value images†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Whole body (vertex to knees): axial, T2-weighted, fast spin-echo without fat suppression, 5-mm contiguous sectioning, multiple stations, preferably matching the diffusion-weighted images</td>
<td>Optional</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>Regional assessments: for example, symptomatic or known sites outside standard field of view, through sites of suspected cord compression, nerve root involvement, extramedullary disease</td>
<td>Usually not</td>
<td>Optional</td>
</tr>
</tbody>
</table>

Note.—ADC = apparent diffusion coefficient, MIP = maximum intensity projection, STIR = short inversion time inversion-recovery, 3D = three-dimensional.

† 5-mm axial imaging may be chosen to match section thickness of diffusion-weighted imaging to facilitate image review.

† Whole-body 3D MIP images displayed as a sequence of coronal or sagittal MIP images rotating in the axial plane (\( \leq 3 \) degrees of rotation per frame) by using an inverted gray scale.
Although useful data are emerging to differentiate normal age-matched bone marrow from diffuse disease by using ADC (47,48,49), whole-marrow quantitative measures of ADC are not yet practical measures and therefore not part of the MY-RADS standard. However, marrow ADC values above 600–700 µm²/sec in a nontreated and newly diagnosed patient with multiple myeloma could be used to increase confidence for the diagnosis of diffuse marrow involvement (8). For patients who have been treated, there is increased potential for false-positive appearances of diffuse infiltration due to rebound hypercellularity related to treatment effects or granulocyte colony–stimulating factor (8). Therefore, when diffuse disease is suspected, administration of granulocyte colony–stimulating factor must be excluded and if progression is suspected based on suspicion for diffuse infiltration alone, then this must be confirmed with serum biochemistry and/or marrow sampling.

**Structured Reporting**

Structured clinical reporting (Table 2) should be performed for each examination. For response assessments, we recommend that response assessment category, or RAC, be assigned according to anatomic regions. For each region, RAC can be assigned by using the criteria given in Table 3. The RAC should use a five-point scale as follows: 1, highly likely to be responding; 2, likely to be responding; 3, stable; 4, likely to be progressing; 5, highly likely to be progressing (Table 3). More detailed case report forms for research are included in Appendix E1 (online).

**Clinical Trial Assessments**

Most clinical reports will be performed as outlined in the previous section. However, academic centers wishing to collect assessments of disease for clinical trials may require more sophisticated scoring systems. Detailed instructions for a proposed clinical trials scoring system and an exemplar case study can be found in Table E2 and Figure E1 (Appendix E1 [online]).

Knowing that quantitative assessments such as ADC and fat fraction measurements can change over time (for example, responding myeloma may show an early increase in ADC values at 4–6 weeks due to cell death, followed by a decrease in ADC with return of normal fatty marrow [51]), it is difficult to be prescriptive regarding the frequency of imaging follow-up. Therefore, for correlation, we recommend that imaging should coincide with clinical routines where serum and marrow assessments are performed.

**Conclusion**

The Myeloma Response Assessment and Diagnosis System (MY-RADS) system provides comprehensive characterization of the myeloma state, both at diagnosis and the start of treatment, as well as over time as the disease evolves during
Table 3: MY-RADS Response Assessment Categories

<table>
<thead>
<tr>
<th>RAC Descriptions’</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1: Highly likely to be responding</td>
<td>Return of normal fat containing marrow in areas previously infiltrated by focal or diffuse myelomatous infiltration</td>
</tr>
<tr>
<td></td>
<td>Unequivocal decrease in number or size of focal lesions</td>
</tr>
<tr>
<td></td>
<td>Conversion of a packed bone marrow infiltrate into discrete nodules, with unequivocal decrease in tumor load in the respective bone marrow space</td>
</tr>
<tr>
<td></td>
<td>Decreasing soft tissue associated with bone disease</td>
</tr>
<tr>
<td></td>
<td>Emergence of intra- or peritumor fat within/around focal lesions (fat dot or halo signs)</td>
</tr>
<tr>
<td></td>
<td>Previously evident lesion shows increase in ADC from ( \leq 1400 , \text{µm}^2/\text{sec} ) to ( &gt;1400 , \text{µm}^2/\text{sec} )</td>
</tr>
<tr>
<td></td>
<td>( \geq 40% ) increase in ADC from baseline with corresponding decrease in normalized high ( b )-value signal intensity; morphologic findings consistent with stable or responding disease</td>
</tr>
<tr>
<td>For soft-tissue disease, RECIST version 1.1 criteria for PR/CR</td>
<td></td>
</tr>
<tr>
<td>2: Likely to be responding</td>
<td>Evidence of improvement but not enough to fulfill criteria for RAC 1. For example:</td>
</tr>
<tr>
<td></td>
<td>Slight decrease in number/size of focal lesions</td>
</tr>
<tr>
<td></td>
<td>Previously evident lesions showing increases in ADC from ( \leq 1000 , \text{µm}^2/\text{sec} ) to ( &lt;1400 , \text{µm}^2/\text{sec} )</td>
</tr>
<tr>
<td></td>
<td>( &gt;25% ) but ( &lt;40% ) increase in ADC from baseline with corresponding decrease in high ( b )-value signal intensity; morphologic findings consistent with stable or responding disease</td>
</tr>
<tr>
<td>For soft-tissue disease, RECIST version 1.1 not meeting requirements for PR</td>
<td></td>
</tr>
<tr>
<td>3: No change</td>
<td>No observable change</td>
</tr>
<tr>
<td>4: Likely to be progressing</td>
<td>Evidence of worsening disease, but not enough to fulfill criteria for RAC 5</td>
</tr>
<tr>
<td></td>
<td>Equivocal appearance of new lesion(s)</td>
</tr>
<tr>
<td></td>
<td>No change in size but increasing signal intensity on high ( b )-value images (with ADC values ( &lt;1400 , \text{µm}^2/\text{sec} )) consistent with possible disease progression</td>
</tr>
<tr>
<td></td>
<td>Relapsed disease: reemergence of lesion(s) that previously disappeared or enlargement of lesion(s) that had partially regressed/stabilized with prior treatments</td>
</tr>
<tr>
<td></td>
<td>Soft tissue in spinal canal causing narrowing not associated with neurologic findings and not requiring radiation therapy</td>
</tr>
<tr>
<td>For soft-tissue disease, RECIST version 1.1 criteria not meeting requirements for PD</td>
<td></td>
</tr>
<tr>
<td>5: Highly likely to be progressing</td>
<td>New critical fracture(s)/cord compression requiring radiation therapy/surgical intervention; only if confirmed as malignant with MRI signal characteristics</td>
</tr>
<tr>
<td></td>
<td>Unequivocal new focal (( &gt;5 ) to 10 mm)/diffuse area(s) of infiltration in regions of previously normal marrow</td>
</tr>
<tr>
<td></td>
<td>Unequivocal increase in number/size of focal lesions</td>
</tr>
<tr>
<td></td>
<td>Evolution of focal lesions to diffuse neoplastic pattern</td>
</tr>
<tr>
<td></td>
<td>Appearance/increasing soft tissue associated with bone disease</td>
</tr>
<tr>
<td></td>
<td>New lesions/regions of high signal intensity on high ( b )-value images with ADC value between 600–1000 ( \mu \text{m}^2/\text{sec} )</td>
</tr>
</tbody>
</table>

Note.— Multiple criteria determine response assessment category (RAC). For RAC 1 or 2, when diffusion-weighted imaging and morphology are discordant, consideration should be given to pitfalls such as T1 pseudoprogression and bone marrow fat reemergence (the latter two may not increase apparent diffusion coefficient [ADC] values). MY-RADS = Myeloma Response Assessment and Diagnosis System, RECIST = Response Evaluation Criteria in Solid Tumors.

‘ RECIST version 1.1 categories for soft-tissue disease are as follows. Complete response (CR): Disappearance of all target lesions. Partial response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Progressive disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Progression of nodes: nodes less than 1.0 cm have to have grown by at least 5 mm in short axis from baseline or treatment nadir and be greater than or equal to 1 cm to be considered to have progressed. Nodes that are 1.0–1.5 cm and have grown by at least 5 mm in short axis from baseline or treatment nadir and are greater than or equal to 1.5 cm in short axis can be considered to have progressed. For nodes greater than or equal to 1.5 cm in short axis, use RECIST version 1.1 progression criteria. Progression of visceral disease: Use RECIST version 1.1 progression criteria above applied to soft-tissue disease. Source.—Reference 54.

therapy and follow-up. MY-RADS recommendations are likely to fulfill the need to promote standardization and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI and allow better response assessments. This system is designed for guiding patient care but has potential for incorporation into clinical trials when lesion measurements become more important. MY-RADS allows the categorization of patients with specific patterns of disease for clinical trial stratification. MY-RADS requires validation within clinical trials, including assessments of reproducibility. We suggest that MY-RADS be evaluated in studies that assess the effects of life-prolonging myeloma treatments, including novel treatment strategies such as immunotherapy. In these studies, MY-RADS assessments of the depth and heterogeneity of response should be compared with established myeloma response criteria. Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, new response categories need to be defined that can identify responses that are deeper than those conventionally defined as complete response.

Correlations with quality-of-life measures, rates of skeletal events, and rates of progression-free survival are also needed. The latter are prerequisites for the introduction of whole-body MRI into longer term follow-up registry studies that prospectively collect appropriate meta-data, which would allow objective assessments of whether whole-body MRI is effective in supporting
patient care and drug development. It is anticipated that, as evidence accrues from clinical trials, more specific recommendations and/or algorithms incorporating MY-RADS will emerge. Thus, we recommend that Myeloma Response Assessment and Diagnos- sis System is now evaluated in clinical trials to assess its impact on the clinical practice of myeloma.

Disclosures of Conflicts of Interest: C.M. Activities related to the present ar- ticle: disclosed no relevant relationships. Activities not related to the present article: received payment for lectures including service on speakers bureaus from Amgen and Takeda; received payment for development of educational presentations from Amgen. Other relationships: disclosed no relevant relationships. J.H. Activities re- lated to the present article: institution received grant from Celgene. Activities not related to the present article: is a consultant for and received payment for lectures, including service on speakers bureaus from Bayer, Curagita, and Siemens; received payment for travel/accommodations/meeting expenses unrelated to activities listed from Bayer, Curagita, and Siemens; other relationships: disclosed no relevant relationships. S.D. disclosed no relevant relationships. E.E.L. disclosed no relevant relationships. L.I.M. dis- closed no relevant relationships. D.J.C. disclosed no relevant relationships. M.D.B. disclosed no relevant relationships. N.A. disclosed no relevant relationships. B.O. disclosed no relevant relationships. H.P.S. Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: is a consultant for and received payment for lectures including service on speakers bureaus from Bayer, Curagita, and Siemens; received payment for travel/accom- modations/meeting expenses unrelated to activities listed from Bayer, Curagita, and Siemens. Other relationships: disclosed no relevant relationships. J.T.A. disclosed no relevant relationships. M.E.K. Activi- ties related to the present article: disclosed no relevant relationships. Activities not related to the present article: is a consultant for and received payment for lectures including service on speakers bureaus from Amgen, Celgene, Janssen, and Takeda; has grants/grants pending with Celgene and Sanofi; received payment for lectures including service on speakers bureaus and payment for travel/accommodations/meeting expenses unrelated to activities listed from Amgen, BMS, Celgene, Janssen, Novartis, and Takeda. Other relationships: disclosed no relevant relationships. S.D. disclosed no relevant relationships. O.L. disclosed no relevant relationships. J.T.A. disclosed no relevant relationships. J.T.A. disclosed no relevant relationships. J.T.A.

References